Markets.com Logo
euEnglish
LoginSign Up

RXRX stock price: Is RXRX a good stock to invest today?

Feb 20, 2025
6 min read
Table of Contents
  • 1. Introduction to RXRX Stock
  • 2. Current RXRX Stock Price
  • 3. Company Overview and Business Model
  • 4. Financial Performance and Valuation
  • 5. Market Sentiment and Analyst Outlook
  • 6. Competitive Landscape and Industry Trends
  • 7. Risks and Challenges
  • 8. Investment Thesis: Is RXRX a Good Buy Today?
  • 9. Conclusion

hands-holding-dollar-banknote-stock-width-1200-format-jpeg.jpg

Is RXRX a good stock to invest today: Recursion Pharmaceuticals (ticker: RXRX) is a biotechnology company that focuses on using advanced technology and machine learning to discover and develop new drugs.
 


Introduction to RXRX Stock


Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to enhance drug discovery. Headquartered in Salt Lake City, Utah, the company aims to decode complex biological systems by integrating biology, chemistry, automation, data science, and engineering. As of February 20, 2025, RXRX is trading on the NASDAQ, and its stock price has garnered attention from investors intrigued by its AI-driven approach to pharmaceuticals. But is it a good stock to invest in today? Let’s break it down by examining its current stock price, financial performance, market trends, and risks.
 


Current RXRX Stock Price


As of the close of trading on February 20, 2025, the exact stock price of RXRX isn’t specified in real-time here, but recent trends can provide context. Based on widely available financial data up to this point, RXRX has experienced volatility typical of biotech stocks. For instance, its 52-week range has fluctuated between approximately $5.60 and $15.74, reflecting significant price swings. On February 14, 2025, posts on X noted the stock at $10.53, with a 24.12% increase that day, suggesting momentum. Assuming stability or slight movement since then, let’s estimate it’s hovering around $10-$11 as of today. Investors should verify the exact price via a financial platform like Yahoo Finance or Nasdaq for the latest figure.

This price reflects a market capitalization of roughly $3 billion, calculated by multiplying the current stock price by its outstanding shares (approximately 286.6 million). While this valuation is modest compared to giants like Moderna, it’s significant for a clinical-stage biotech without marketed products, raising questions about its investment potential.
 


Company Overview and Business Model


Recursion Pharmaceuticals stands out by merging biotech with technology. Its Recursion Operating System (OS) uses AI to analyze vast biological and chemical datasets, aiming to identify drug candidates faster and more efficiently than traditional methods. The company’s pipeline includes therapies like REC-994 (Phase 2 for cerebral cavernous malformation), REC-2282 (Phase 2/3 for neurofibromatosis type 2), and REC-4881 (Phase 1b/2 for familial adenomatous polyposis), among others. These candidates target rare diseases and cancers, areas with high unmet needs.

Unlike revenue-generating pharma firms, Recursion is pre-commercial, relying on investor funding and partnerships (e.g., with Bayer, Roche, and Takeda) to fuel its research. This model promises innovation but carries inherent risks, as success hinges on clinical trial outcomes and regulatory approvals—both uncertain and years away.
 


Financial Performance and Valuation


Recursion’s financials reflect its early-stage status. In 2023, it reported $44.58 million in revenue, up 11.88% from $39.84 million in 2022, primarily from collaboration agreements. However, losses widened to $328.07 million, a 37% increase from 2022, driven by R&D expenses. As of its latest quarterly report (likely Q4 2024, released in early 2025), analysts expected an EPS of around -$0.34, with estimates ranging from -$0.70 to -$0.29, indicating ongoing unprofitability.

With a price-to-book ratio around 5.75x (higher than the biotech industry average of 4.77x), RXRX appears expensive relative to its tangible assets. Its negative price-to-earnings ratio (e.g., -6.89) is typical for a loss-making biotech, shifting focus to future potential rather than current earnings. Cash reserves and burn rate are critical here—Recursion has historically raised funds via stock offerings (e.g., $436 million IPO in 2021), but investors should monitor its liquidity to ensure it can sustain operations through clinical milestones.
 


Market Sentiment and Analyst Outlook


Market sentiment on RXRX is mixed but leans cautiously optimistic. Analysts from firms like KeyBanc (Overweight, $16 target) and others peg a 12-month average price target around $10.33-$11, suggesting modest upside from a $10-$11 base. Ratings typically split between “Buy” (2/6 analysts) and “Hold” (4/6), per sources like TipRanks, reflecting uncertainty about its AI platform’s validation.

Investor enthusiasm spiked with high-profile backing—Cathie Wood’s ARK Invest holds a significant stake (valued at $216 million recently), and SoftBank filed a new position in February 2025. Nvidia’s $50 million investment in 2023 further ties RXRX to the AI hype cycle. Posts on X highlight bullish technicals (e.g., MACD and whale accumulation), yet skepticism persists about trial data, with some questioning if “safety” endpoints overshadow efficacy.
 


Competitive Landscape and Industry Trends


Recursion operates in a crowded biotech-AI intersection, competing with firms like Exscientia (which it acquired for $688 million in 2024), Insitro, and BenevolentAI. The Exscientia deal bolsters its chemical synthesis capabilities, potentially yielding $100 million in annual synergies, but integration risks remain. Broader industry trends favor AI in drug discovery—valued at $125 billion by 2028 per some forecasts—driven by the promise of reduced costs and timelines (traditional drug development takes 10-15 years and $1-2 billion per drug).

However, AI’s track record in biotech is nascent. While Recursion’s platform has identified candidates, no AI-derived drug from any company has yet reached market approval, tempering expectations. Competitors with stronger clinical progress or diversified pipelines might outpace RXRX if it stumbles.
 


Risks and Challenges


Investing in RXRX carries substantial risks:
Clinical Risk: Recent Phase 2 data for REC-994 showed safety but mixed efficacy, disappointing some (e.g., X posts called it “sucked”). Failure to prove AI’s edge in trials could erode confidence.
Financial Risk: High cash burn and no near-term revenue mean reliance on dilutive funding.
Market Risk: Biotech stocks are volatile, and RXRX’s 14.11% daily volatility (per TradingView) amplifies this.
Regulatory Risk: FDA approval is years away, with no guarantee of success.
Hype Risk: AI-driven stocks can inflate beyond fundamentals, risking corrections.
A biotech veteran might argue RXRX’s valuation reflects hope, not results—a common pitfall in this sector.
 


Investment Thesis: Is RXRX a Good Buy Today?


So, is RXRX a good investment on February 20, 2025? It depends on your risk tolerance and horizon:
Bull Case: If Recursion’s AI platform delivers a breakthrough (e.g., REC-994 or REC-2282 advancing to Phase 3 with strong efficacy), the stock could soar—analysts’ high target of $16 implies 45-60% upside from $10-$11. Partnerships and acquisitions signal growth potential, and AI’s long-term promise could disrupt pharma.
Bear Case: Without “definitive wins” (as JPMorgan noted), RXRX risks languishing as an overhyped story stock. Ongoing losses, trial setbacks, and dilution could drag it below $6 (Jefferies’ low target), a 40-45% drop.
For a balanced view, RXRX is a speculative play. Its current price likely embeds optimism from AI buzz and institutional backing, but tangible progress lags. A “Hold” stance aligns with analyst consensus—accumulate on dips (e.g., $8-$9) but avoid chasing at peaks.
 


Conclusion


Recursion Pharmaceuticals (RXRX) embodies the high-risk, high-reward ethos of biotech investing. At $10-$11, it’s neither a screaming bargain nor grossly overvalued, sitting in a wait-and-see zone. Investors bullish on AI’s future in drug discovery might allocate a small portfolio slice (e.g., 2-5%), betting on long-term upside. Cautious types should watch for stronger clinical data or a pullback before diving in. As always, diversify, research deeply, and check real-time prices before acting—biotech’s rollercoaster spares no one.


When considering shares, indices, forex (foreign exchange) and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss. 

Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice.
 


Risk Warning: this article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform.When considering shares, indices, forex (foreign exchange) and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice. Trading cryptocurrency CFDs and spread bets is restricted for all UK retail clients. 

Frances Wang
Written by
Frances Wang
SHARE

Markets

  • Palladium - Cash

    chartpng

    --

    -1.12%
  • EUR/USD

    chartpng

    --

    0.33%
  • Cotton

    chartpng

    --

    -0.37%
  • AUD/USD

    chartpng

    --

    0.22%
  • Santander

    chartpng

    --

    0.95%
  • Apple.svg

    Apple

    chartpng

    --

    -0.27%
  • easyJet

    chartpng

    --

    0.79%
  • VIXX

    chartpng

    --

    -0.90%
  • Silver

    chartpng

    --

    -0.45%
Most Popular ArticlesView all
  • Mar 10, 2025

    Trump stock price: Shares of Trump Media fell more than 11%

Table of Contents
  • 1. Introduction to RXRX Stock
  • 2. Current RXRX Stock Price
  • 3. Company Overview and Business Model
  • 4. Financial Performance and Valuation
  • 5. Market Sentiment and Analyst Outlook
  • 6. Competitive Landscape and Industry Trends
  • 7. Risks and Challenges
  • 8. Investment Thesis: Is RXRX a Good Buy Today?
  • 9. Conclusion

Related Articles

AMD Stock Is down Today: What Happened to Advanced Micro Devices Inc?

AMD Stock Is down Today: Advanced Micro Devices Inc. (AMD) has been a key player in the semiconductor industry, known for its innovative products and competitive edge against rivals.

Ghko B|1 day ago

Crypto market today: Trump Supports Cryptos, BTC/USD over $119K

Crypto market today: the cryptocurrency market continues to evolve rapidly, influenced by various factors, including political endorsements, market dynamics, and technological advancements.

Ghko B|1 day ago

What is VOO: how to trade Vanguard S&P 500 ETF CFD with markets.com?

What is VOO: the Vanguard S&P 500 ETF (VOO) is one of the most popular exchange-traded funds (ETFs) that aims to track the performance of the S&P 500 index.

Ghko B|1 day ago
Markets.com Logo
google playapp storeweb tradertradingView

Contact Us

support@markets.com+12845680155

Markets

  • Forex
  • Shares
  • Commodities
  • Indices
  • Crypto
  • ETFs
  • Bonds

Trading

  • Trading Tools
  • Platform
  • Web Platform
  • App
  • TradingView
  • MT4
  • MT5
  • CFD Trading
  • CFD Asset List
  • Trading Info
  • Trading Conditions
  • Trading Hours
  • Trading Calculators
  • Economic Calendar

Learn

  • News
  • Trading Basics
  • Glossary
  • Webinars
  • Traders' Clinic
  • Education Centre

About

  • Why markets.com
  • Global Offering
  • Our Group
  • Careers
  • FAQs
  • Legal Pack
  • Safety Online
  • Complaints
  • Contact Support
  • Help Centre
  • Sitemap
  • Cookie Disclosure
  • Awards and Media

Promo

  • Gold Festival
  • Crypto Trading
  • marketsClub
  • Welcome Bonus
  • Loyal Bonus
  • Referral Bonus

Partnership

  • Affiliation
  • IB

Follow us on

  • Facebook
  • Instagram
  • Twitter
  • Youtube
  • Linkedin
  • Threads
  • Tiktok

Listed on

  • 2023 Best Trading Platform Middle East - International Business Magazine
  • 2023 Best Trading Conditions Broker - Forexing.com
  • 2023 Most Trusted Forex Broker - Forexing.com
  • 2023 Most Transparent Broker - AllForexBonus.com
  • 2024 Best Broker for Beginners, United Kingdom - Global Brands Magazine
  • 2024 Best MT4 & MT5 Trading Platform Europe - Brands Review Magazine
  • 2024 Top Research and Education Resources Asia - Global Business and Finance Magazine
  • 2024 Leading CFD Broker Africa - Brands Review Magazine
  • 2024 Best Broker For Beginners LATAM - Global Business and Finance Magazine
  • 2024 Best Mobile Trading App MENA - Brands Review Magazine
  • 2024 Best Outstanding Value Brokerage MENA - Global Business and Finance Magazine
  • 2024 Best Broker for Customer Service MENA - Global Business and Finance Magazine
LegalLegal PackCookie DisclosureSafety Online

Payment
Methods

mastercardvisanetellerskrillwire transferzotapay
The www.markets.com/za/ site is operated by Markets South Africa (Pty) Ltd which is a regulated by the FSCA under license no. 46860 and licensed to operate as an Over The Counter Derivatives Provider (ODP) in terms of the Financial Markets Act no.19 of 2012. Markets South Africa (Pty) Ltd is located at BOUNDARY PLACE 18 RIVONIA ROAD, ILLOVO SANDTON, JOHANNESBURG, GAUTENG, 2196, South Africa. 

High Risk Investment Warning: Trading Foreign Exchange (Forex) and Contracts For Difference (CFDs) is highly speculative, carries a high level of risk and is not appropriate for every investor. You may sustain a loss of some or all of your invested capital, therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. Please read the full  Risk Disclosure Statement which gives you a more detailed explanation of the risks involved.

For privacy and data protection related complaints please contact us at privacy@markets.com. Please read our PRIVACY POLICY STATEMENT for more information on handling of personal data.

Markets.com operates through the following subsidiaries:

Safecap Investments Limited, which is regulated by the Cyprus Securities and Exchange Commission (“CySEC”) under license no. 092/08. Safecap is incorporated in the Republic of Cyprus under company number ΗΕ186196.

Markets International Limited is registered  in the Saint Vincent and The Grenadines (“SVG”) under the revised Laws of Saint Vincent and The Grenadines 2009, with registration number  27030 BC 2023.

Close
Close

set cookie

set cookie

We use cookies to do things like offer live chat support and show you content we think you’ll be interested in. If you’re happy with the use of cookies by markets.com, click accept.